Chronic Myeloproliferative Disorders Terminated Phase 3 Trials for Moxifloxacin (DB00218)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00324324Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantSupportive Care